Mission Bio raises $30M in Series B round to develop genomics platform
The company said it would use the funding to expand its single-cell DNA sequencing platform into CRISPR applications and global markets.
Agilent buys cell metabolism tech company Seahorse Bio for $235M
Agilent Technologies will expand research on cell metabolism to better understand things like neurodegeneration, aging, cancer, cardiovascular disease and cell physiology with its acquisition of Seahorse Bioscience.
presented by
Could QuantalX’s Device Make Managing Brain Health Easier?
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.